Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1986 May;88(1):221–230. doi: 10.1111/j.1476-5381.1986.tb09490.x

Effects of Bay K 8644 and nifedipine on femoral arteries of spontaneously hypertensive rats.

K Aoki, M Asano
PMCID: PMC1917113  PMID: 2423174

Abstract

Vasoconstrictor effects of Bay K 8644 (an agonist known to increase Ca2+ influx through the voltage-dependent Ca2+ channels) on femoral arteries of 6 week old spontaneously hypertensive rats (SHR) were investigated, and data compared with findings in age-matched normotensive Wistar-Kyoto rats (WKY). The addition of Bay K 8644 (1 X 10(-10)-3 X 10(-7) M) elicited a dose-dependent contraction in SHR femoral artery in the absence of any contractile agent. Maximum contraction induced by this agonist was the same as the maximum induced by either K+-depolarization or alpha-adrenoceptor stimulation. Bay K 8644 was less effective in eliciting a contraction in the WKY femoral artery. Increased sensitivity to K+ was also observed in the SHR femoral artery. In contrast, contractions in response to alpha-adrenoceptor stimulation were the same in the SHR as those in the WKY. The addition of nifedipine, a Ca2+ channel antagonist, to an unstimulated preparation produced a dose-dependent relaxation in femoral arteries from SHR, but not from WKY. When the arteries were contracted with 60 mM K+, nifedipine produced similar relaxations in the SHR as those in the WKY, suggesting that the Ca2+ channels in the SHR femoral arteries are more activated than those in the WKY femoral arteries. Contractile responses to SHR femoral arteries to Bay K 8644 were antagonized competitively by nifedipine. Contractile responses to Ca2+ determined in K+-depolarized strips were also antagonized competitively by nifedipine. However, Schild plot analysis demonstrated a different pA2 value for nifedipine, suggesting that there may be a difference in the state of voltage-dependent Ca2+ channels in SHR femoral artery between the stimulation with Bay K 8644 and K+-depolarization.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Asano M., Aoki K., Matsuda T. Quantitative changes of maximum contractile response to norepinephrine in mesenteric arteries from spontaneously hypertensive rats during the development of hypertension. J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):727–731. doi: 10.1097/00005344-198407000-00028. [DOI] [PubMed] [Google Scholar]
  3. Asano M., Aoki K., Matsuda T. Reduced beta adrenoceptor interactions of norepinephrine enhance contraction in the femoral artery from spontaneously hypertensive rats. J Pharmacol Exp Ther. 1982 Oct;223(1):207–214. [PubMed] [Google Scholar]
  4. Asano M., Hidaka H. Pharmacological properties of N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), a calmodulin antagonist in arterial strips from rats and rabbits. J Pharmacol Exp Ther. 1985 Aug;234(2):476–484. [PubMed] [Google Scholar]
  5. Bolton T. B. Mechanisms of action of transmitters and other substances on smooth muscle. Physiol Rev. 1979 Jul;59(3):606–718. doi: 10.1152/physrev.1979.59.3.606. [DOI] [PubMed] [Google Scholar]
  6. FURCHGOTT R. F., BHADRAKOM S. Reactions of strips of rabbit aorta to epinephrine, isopropylarterenol, sodium nitrite and other drugs. J Pharmacol Exp Ther. 1953 Jun;108(2):129–143. [PubMed] [Google Scholar]
  7. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977;17:149–166. doi: 10.1146/annurev.pa.17.040177.001053. [DOI] [PubMed] [Google Scholar]
  8. Gopalakrishnan V., Park L. E., Triggle C. R. The effect of the calcium channel agonist, Bay K-8644 on human vascular smooth muscle. Eur J Pharmacol. 1985 Jul 31;113(3):447–451. doi: 10.1016/0014-2999(85)90095-0. [DOI] [PubMed] [Google Scholar]
  9. Hashimoto K., Takeda K., Katano Y., Nakagawa Y., Tsukada T., Hashimoto T., Shimamoto N., Sakai K., Otorii T., Imai S. Effects of niludipine (Bay a 7168) on the cardiovascular system with a note on its calcium-antagonistic effects. Arzneimittelforschung. 1979;29(9):1368–1373. [PubMed] [Google Scholar]
  10. Hess P., Lansman J. B., Tsien R. W. Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists. Nature. 1984 Oct 11;311(5986):538–544. doi: 10.1038/311538a0. [DOI] [PubMed] [Google Scholar]
  11. Holloway E. T., Bohr D. F. Reactivity of vascular smooth muscle in hypertensive rats. Circ Res. 1973 Dec;33(6):678–685. doi: 10.1161/01.res.33.6.678. [DOI] [PubMed] [Google Scholar]
  12. Kanmura Y., Itoh T., Kuriyama H. Agonist actions of Bay K 8644, a dihydropyridine derivative, on the voltage-dependent calcium influx in smooth muscle cells of the rabbit mesenteric artery. J Pharmacol Exp Ther. 1984 Dec;231(3):717–723. [PubMed] [Google Scholar]
  13. Mikkelsen E., Nyborg N. C., Kazda S. A novel 1,4 dihydropyridine, BAY K 8644, with contractile effects on vascular smooth muscle. Acta Pharmacol Toxicol (Copenh) 1985 Jan;56(1):44–49. doi: 10.1111/j.1600-0773.1985.tb01251.x. [DOI] [PubMed] [Google Scholar]
  14. Mulvany M. J. Do resistance vessel abnormalities contribute to the elevated blood pressure of spontaneously-hypertensive rats? A review of some of the evidence. Blood Vessels. 1983;20(1):1–22. doi: 10.1159/000158455. [DOI] [PubMed] [Google Scholar]
  15. OKAMOTO K., AOKI K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J. 1963 Mar;27:282–293. doi: 10.1253/jcj.27.282. [DOI] [PubMed] [Google Scholar]
  16. Rosenberger L. B., Ticku M. K., Triggle D. J. The effect of Ca2+ antagonists on mechanical responses and Ca2+ movements in guinea pig ileal longitudinal smooth muscle. Can J Physiol Pharmacol. 1979 Apr;57(4):333–347. doi: 10.1139/y79-052. [DOI] [PubMed] [Google Scholar]
  17. Salaices M., Marin J., Sanchez-Ferrer C. F., Reviriego J. The effects of BAY-K-8644 on the contraction of cat middle cerebral and femoral arteries. Biochem Pharmacol. 1985 Sep 1;34(17):3131–3135. doi: 10.1016/0006-2952(85)90158-3. [DOI] [PubMed] [Google Scholar]
  18. Schramm M., Thomas G., Towart R., Franckowiak G. Activation of calcium channels by novel 1,4-dihydropyridines. A new mechanism for positive inotropics or smooth muscle stimulants. Arzneimittelforschung. 1983;33(9):1268–1272. [PubMed] [Google Scholar]
  19. Spedding M. Assessment of "Ca2+ -antagonist" effects of drugs in K+ -depolarized smooth muscle. Differentiation of antagonist subgroups. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):234–240. doi: 10.1007/BF00500485. [DOI] [PubMed] [Google Scholar]
  20. Su C. M., Swamy V. C., Triggle D. J. Calcium channel activation in vascular smooth muscle by BAY K 8644. Can J Physiol Pharmacol. 1984 Nov;62(11):1401–1410. doi: 10.1139/y84-233. [DOI] [PubMed] [Google Scholar]
  21. Uski T. K., Andersson K. E. Some effects of the calcium promotor BAY K 8644 on feline cerebral arteries. Acta Physiol Scand. 1985 Jan;123(1):49–53. doi: 10.1111/j.1748-1716.1985.tb07559.x. [DOI] [PubMed] [Google Scholar]
  22. Webb R. C., Bohr D. F. Recent advances in the pathogenesis of hypertension: consideration of structural, functional, and metabolic vascular abnormalities resulting in elevated arterial resistance. Am Heart J. 1981 Aug;102(2):251–264. doi: 10.1016/s0002-8703(81)80016-6. [DOI] [PubMed] [Google Scholar]
  23. Webb R. C., Vanhoutte P. M., Bohr D. F. Adrenergic neurotransmission in vascular smooth muscle from spontaneously hypertensive rats. Hypertension. 1981 Jan-Feb;3(1):93–103. doi: 10.1161/01.hyp.3.1.93. [DOI] [PubMed] [Google Scholar]
  24. Winquist R. J., Webb R. C., Bohr D. F. Vascular smooth muscle in hypertension. Fed Proc. 1982 Jun;41(8):2387–2393. [PubMed] [Google Scholar]
  25. Yamamoto H., Hwang O., Van Breemen C. Bay K8644 differentiates between potential and receptor operated Ca2+ channels. Eur J Pharmacol. 1984 Jul 20;102(3-4):555–557. doi: 10.1016/0014-2999(84)90581-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES